Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 10Gynecologic 10Genitourinary 8Gastrointestinal 8Sarcoma 6CNS 5Breast 4Other solid neoplasm 3Head & Neck 2Tumor-Agnostic 1Other hematologic neoplasm 1Endocrine 1Dermatologic 1

Conditions

Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Adenocarcinoma, Follicular 1

Interventions

Cisplatin 136Cetuximab 101pembrolizumab 83Radiotherapy 62Carboplatin 57Radiotherapy, Intensity-Modulated 54Fluorouracil 47Docetaxel 47Nivolumab 44Paclitaxel 37Radiation 21Erlotinib Hydrochloride 19durvalumab 18Platinum 15Ipilimumab 14Gemcitabine 13lenvatinib 12Drug Therapy 12Bevacizumab 12Albumin-Bound Paclitaxel 12vandetanib 11Pemetrexed 11Magnetic Resonance Spectroscopy 111,2-diaminocyclohexaneplatinum II citrate 11Radiosurgery 10Everolimus 10tremelimumab 9epacadostat 9Surgical Procedures, Operative 9Sorafenib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × cediranib × Head & Neck × Clear all
NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT00243347 2013-10-17

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

AstraZeneca

Phase 1 Completed
19 enrolled 7 charts
Head & NeckThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡